Database release
In this release, we add two recent precision oncology approvals from the FDA regarding ER signaling inhibition in two cancer types.
Added entries:
- (FDA) ERBB2 copy number amplifications and sensitivity to trastuzumab in combination with tucatinib in colorectal cancer.
- (FDA) ESR1 somatic variants and sensitivity to elacestrant in breast cancer.